"We're excited to continue building our partnership with Medidata," said Kevin Schwarz, CTI's chief operating officer. "By streamlining trial operations, improving data input and output, and providing better trial oversight, the Medidata platform allows us to conduct faster, more insightful research—and ultimately help our sponsors bring more effective therapies to the acutely ill patients they serve."
Specializing in a number of emerging research areas—including rare/orphan diseases, gene and stem cell therapy, transplantation, immunology and other areas involving critically ill patient populations—CTI offers a full spectrum of Phase I-IV clinical trial services to pharmaceutical and biotechnology companies. To optimize clinical trial processes, improve data accessibility and efficiently track study progress, CTI has implemented Medidata's integrated solutions for electronic data capture (Medidata Rave®), clinical trial management (Medidata CTMS™) and medical coding (Medidata Coder®).
"Incorporating the Medidata platform in our clinical trials has enabled our study teams to be much more productive," said Louis Minham, senior director, information technology at CTI. "As a single source of truth, the unified platform lets us view comprehensive trial information in one central location and be more effective in how we extract, share and analyze data—allowing for faster and smarter business decisions. We look forward to bringing many more trials onto the platform in the near future."
A Medidata Services Partner since 2012, CTI has attained accreditations in Rave, CTMS and Coder. The CRO's dedication to expanding its use of the Medidata Clinical Cloud further reinforces CTI's commitment to overcoming critical cost, risk and efficiency challenges throughout the clinical trial lifecycle, thus enabling greater focus on providing therapeutic expertise to clients.
"We are thrilled to be working with CTI, a world-class CRO with unique and highly specialized therapeutic expertise," said Medidata's SVP of global partner business and program, Pat Bernard. "At Medidata we share CTI's mission of conducting high-quality clinical research, and we're proud that our innovative technology is powering trials that benefit the lives of critically and chronically ill patients."
Connect with Medidata:
- Read our blog, Geeks Talk Clinical
- Tweet this: [email protected] expands use of the @Medidata #cloud platform to optimize #clinicaltrial processes & data availability http://bit.ly/1b0nhMr
- Follow us on Twitter: @Medidata
- Find us on LinkedIn
About CTI Clinical Trial and Consulting Services
CTI Clinical Trial and Consulting Services is an innovative, international drug and device development organization that delivers a full spectrum of clinical trial and consulting services from bench to commercialization with a focus on immunology and a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. CTI's focused therapeutic approach provides pharmaceutical, biotechnology and startup firms with clinical and disease area expertise from a unique mix of academic, medical and industry specialists; rich intellectual capital in transplantation, immunology, infectious diseases, hematology, cardiology, nephrology, hepatology, regenerative medicine and rare diseases; flexible study designs that accelerate development programs and deliver high approval ratings that are among the best in the industry; and exceptional global project management and gold standard safety and data management systems that strengthen their program's success potential. Established in 1999 and headquartered in Cincinnati, OH; CTI has offices in North America, Europe, Latin America and Pac-Asia. For additional information, please visit www.ctifacts.com.
About Medidata Solutions
Medidata is the leading global provider of cloud-based solutions for clinical research in life sciences, transforming clinical development through its advanced applications and intelligent data analytics. The Medidata Clinical Cloud® brings new levels of productivity and quality to the clinical testing of promising medical treatments, from study design and planning through execution, management and reporting. We are committed to advancing the competitive and scientific goals of global customers, which include over 90% of the top 25 global pharmaceutical companies; innovative biotech, diagnostic and device firms; leading academic medical centers; and contract research organizations.